TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05044546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Description: Participate in BA counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Description: Participate in BA counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in focus group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Participate in health and wellness education counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Participate in health and wellness education counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Participate in smoking cessation counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Participate in smoking cessation counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Participate in smoking cessation counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Participate in smoking cessation counseling
Study: NCT05382793

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: No iodine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: No iodine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodide (150 μg/day)
Description: A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodide (150 μg/day)
Description: A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine (300 μg/day)
Description: Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine (300 μg/day)
Description: Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide
Study: NCT05697237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: Carrelizumab 200mg/3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solfantinib
Description: Solfantinib 300mg/d
Study: NCT05068739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PA-EMR
Description: Standard oval-shaped, braided wire polypectomy snare with 10 mm or 20 mm loop diameter will be used. With the duodenoscope in a semi-long position, the tip of the snare will be anchored just below the transverse fold of the ampulla and opened above-downwards fashion until the orifice will be seen. The orifice will be strictly preserved to avoid the risk of PEP and approximately the upper two-thirds of the ampullary mound will be grabbed by the snare. The direction and the depth will be controlled by combined movements of the elevator and wheels of the duodenoscope. After removal of the mucosa, the wall of choledochus will be seen clearly and standard wire-guided cannulation (WGC) will be performed. If cannulation can not be achieved with WGC, an additional incision will be performed to the wall of the choledochus with a needle knife.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NKF
Description: The needle knife will be placed at the junction of the upper one-third and lower two-thirds of the papillary roof (bulging portion). Minimal, superficial incisions will be made in the 11-12 o'clock direction. The length of the fistulotomy will be at the endoscopist's discretion, depending on the shape of the papilla. The cut will be extended until bile juice, the pinkish bile duct mucosa, and/or the bulging of the white sphincter of the Oddi's muscle is visible.
Study: NCT06436963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: narrative medicine training combined with CBL training
Description: The experimental group received narrative medicine training combined with CBL training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBL training
Description: The control group received normal CBL training.
Study: NCT05545241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback + BART/EEG
Description: 10 sessions of emotional neurofeedback (max of 2 sessions per week and max of 10 weeks).~Before (Baseline, Day 0) and at the study completion (after 10 neurofeedback sessions, Week 5), a EEG record is realized during the BART, assessing risk-taking behavior.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: BART/EEG only
Description: only the twice EEG record are realized during the BART, assessing risk-taking behavior (every corresponding to the pre and post-neurofeedback evaluations in arm I)
Study: NCT05196984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENUS device (Active Settings)
Description: Participants in the active condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to active 40Hz settings for 30-60 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENUS device (Active Settings)
Description: Participants in the active condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to active 40Hz settings for 30-60 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS device (Sham Settings)
Description: Participants in the control condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to sham settings for 30-60 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS device (Sham Settings)
Description: Participants in the control condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to sham settings for 30-60 minutes.
Study: NCT06447662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07934040
Description: panKRAS inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy (antimetabolite)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Taxane-type Chemotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Monoclonal Antibody (EGFR Inhibitor)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Part of FOLFOX chemotherapy regimen~Folic Acid Analog

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: VEG-F inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immune checkpoint inhibitor (PD-1 inhibitor)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immune checkpoint inhibitor (PD-1 inhibitor)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Can be used in Platinum-based Chemotherapy regimen~Antimetabolite

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Can be used in Platinum-based chemotherapy regimen~Taxane

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)
Study: NCT06370871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigimadlin
Description: Brigimadlin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Solution for infusion
Study: NCT06307756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music group
Description: Mothers will be informed about the application before the procedure. Mothers who agree to participate in the study will be asked to listen to music that relaxes them for 20 minutes a day for 4 days. The mothers' state anxiety levels and milk quantities will be evaluated before starting the application and every day during the application. Mothers' anxiety levels will be evaluated with the State Anxiety Inventory. Mothers' anxiety levels and milk quantities will be evaluated every day at 11.45 when they come to the NICU to express milk.
Study: NCT04967547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-care PD ability assessment form
Description: Subjects will be evaluated using the self-care PD feasibility assessment tool within 7 days after randomization. The evaluation results will be provided to the patient on the same day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education on renal replacement therapy and dialysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education on renal replacement therapy and dialysis
Study: NCT05431023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumonia treatment
Description: Antibiotics for pneumonia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumonia treatment
Description: Antibiotics for pneumonia
Study: NCT06112158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: The BSE training program for the early diagnosis of breast cancer will be offered to students in two ways: face-to-face and via web support.~Content of training Session 1: Topics such as the structure of the breast, the definition of breast cancer, its prevalence, risk factors and symptoms Session 2: Teaching the importance of early diagnosis in breast cancer, the importance and benefits of BSE, the technique of performing BSE, the obstacles to the application of BSE.~Session 3: Teaching the risk factors that cause breast cancer. Session 4: Discussion of case reports of patients diagnosed with breast cancer. Supporting education with web support
Study: NCT06153823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: child behavior management will be done by using VR glasses distraction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tell Show and Do
Description: child behavior management will be done by using tell show and do technique
Study: NCT05848492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole will be given for prevention of invasive candidiasis in preterm and very low birthweight babies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% Saline 2cc intravenous will be given to preterm babies in placebo group.
Study: NCT06093646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ebola+D intervention
Description: Ebola+D intervention will include psycho-education, Problem Solving Therapy, antidepressant medication and referral to a supervising specialist mental health worker.
Study: NCT06027918

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.
Study: NCT04751461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: P0213417, a 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: P0213417, a 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: P0213417, a 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: P0213417, a 2.4% nicotine ENDS product
Study: NCT06027918

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.
Study: NCT04829032

Intervention type: PROCEDURE
Intervention: Hartmann's procedure
Description: Hartmann's procedure
Study: NCT04721119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Infiltration Anesthetic
Description: For the local infiltration anesthetic, patients will receive 20 cc of 0.5% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Infiltration Anesthetic + Adductor Canal Block
Description: For the local infiltration anesthetic, patients will receive 20 cc of 0.25% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision. For the adductor canal block, patients will receive 20 cc of 0.25% ropivicaine, through injection performed by the anesthesiologist. The injection is done under the sartorius muscle, in mid-thigh, using ultrasound guidance.
Study: NCT04641663

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-target Dietary Supplement (MTDS)
Description: The Multi-Target Dietary Supplement (MTDS) is comprised of 51 ingredients designed to simultaneously target and support the cellular processes implicated in the progression of the aging phenotype (oxidative stress, inflammatory processes, insulin resistance, and membrane and mitochondrial deterioration). The MTDS is unique in that it was specifically designed as a multi-target intervention to support the complex cellular perturbations associated with aging. Components of the formulation were chosen based on scientific consensus of documented effectiveness for one or more of the targeted processes, long-term evidence of safety, and synergistic or additive interactions between components.~The MTDS is divided into morning and evening doses to maximize availability of the components to the peak activity level of the cellular processes that require those components.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-target Dietary Supplement (MTDS)
Description: The Multi-Target Dietary Supplement (MTDS) is comprised of 51 ingredients designed to simultaneously target and support the cellular processes implicated in the progression of the aging phenotype (oxidative stress, inflammatory processes, insulin resistance, and membrane and mitochondrial deterioration). The MTDS is unique in that it was specifically designed as a multi-target intervention to support the complex cellular perturbations associated with aging. Components of the formulation were chosen based on scientific consensus of documented effectiveness for one or more of the targeted processes, long-term evidence of safety, and synergistic or additive interactions between components.~The MTDS is divided into morning and evening doses to maximize availability of the components to the peak activity level of the cellular processes that require those components.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-target Dietary Supplement (MTDS)
Description: The Multi-Target Dietary Supplement (MTDS) is comprised of 51 ingredients designed to simultaneously target and support the cellular processes implicated in the progression of the aging phenotype (oxidative stress, inflammatory processes, insulin resistance, and membrane and mitochondrial deterioration). The MTDS is unique in that it was specifically designed as a multi-target intervention to support the complex cellular perturbations associated with aging. Components of the formulation were chosen based on scientific consensus of documented effectiveness for one or more of the targeted processes, long-term evidence of safety, and synergistic or additive interactions between components.~The MTDS is divided into morning and evening doses to maximize availability of the components to the peak activity level of the cellular processes that require those components.
Study: NCT05665972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala coloring
Description: Each participant will be given 12 colored felt-tip pen paint sets and 12 mandala coloring pages by the researchers. Participants will be asked to dye for 3 menstrual cycles, 14 days before the start of menstruation, 1 day a week, at any time of the day and for an average of 20-30 minutes each time.
Study: NCT04977297

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Move to Music Intervention (M2M)
Description: The move to music (M2M) intervention pairs exercise with only music (no video), providing only audio stimulation. The intervention will be provided via an audio playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
Study: NCT04204668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMR
Description: Surgical procedure to connect injured proximal nerve stumps to motor nerve branches directly innervating a muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RPNI
Description: Surgical procedure to wrap the ends of injured nerves in small muscle grafts

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VDMT
Description: Surgical procedure that creates a small muscle graft that is both denervated and vascularized, which will then receive the damaged nerve ending
Study: NCT06159556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peanut intake
Description: Participants will consume 2 ounces of peanuts/peanut butter for 12 weeks
Study: NCT06078709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Undergo EUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET and PET/CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study: NCT05111600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation
Description: Implantation of autologous cultured grafts containing genetically modified stem cells for restoration of functional skin on pre-selected areas
Study: NCT06376565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Complete clinic EHR interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive scheduling reminders

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive reminders and pending EHR orders

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies